Epalex is a specialty pharmaceutical development company with the mission of creating breakthrough therapies that provide an improved quality of life for patients with neurological disorders.
Epalex is developing novel treatments for migraine and epilepsy. The company is advancing a range of molecules protected by issued and pending United States and worldwide patents covering the chemical compositions of the active ingredients and the method of uses in epilepsy and migraine.
Initial product development was supported by the University of California, Davis and research grants from the Epilepsy Therapy Project, the Epilepsy Foundation, and the National Institutes of Health through the National Center for Advancing Translational Sciences.
The potential United States market for the company's products include the estimated 3 million adults and 470,000 children with epilepsy and a substantial number of the estimated 35 million Americans with migraine.
Initial product development was supported by the University of California, Davis and research grants from the Epilepsy Therapy Project, the Epilepsy Foundation, and the National Institutes of Health through the National Center for Advancing Translational Sciences.
The potential United States market for the company's products include the estimated 3 million adults and 470,000 children with epilepsy and a substantial number of the estimated 35 million Americans with migraine.
Epalex is a proud recipient of the Innovation Seal of Excellence award of the Epilepsy Foundation of America, which is designed to accelerate the advancement of research from the laboratory to the patient.
